CN101856405A - Medicinal composition for treating type II diabetes mellitus and preparation method thereof - Google Patents
Medicinal composition for treating type II diabetes mellitus and preparation method thereof Download PDFInfo
- Publication number
- CN101856405A CN101856405A CN 200910048888 CN200910048888A CN101856405A CN 101856405 A CN101856405 A CN 101856405A CN 200910048888 CN200910048888 CN 200910048888 CN 200910048888 A CN200910048888 A CN 200910048888A CN 101856405 A CN101856405 A CN 101856405A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- fructus
- diabetes mellitus
- ligustri lucidi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicinal composition for treating type II diabetes mellitus and a preparation method thereof. The medicinal composition comprises the following components in part by weight: 10 to 60 parts of astragalus, 10 to 100 parts of glossy ganoderma, 5 to 30 parts of glossy privet fruit and 6 to 30 parts of dark plum fruit. The medicinal composition of the invention can reduce fasting blood glucose and postprandial blood glucose and glycated hemoglobin effectively and relieve inflammation symptoms effectively, and has the good improved effect on the insulin resistance of patients who suffer from the type II diabetes mellitus.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation method thereof, be specifically related to a kind of pharmaceutical composition for the treatment of type 2 diabetes mellitus and preparation method thereof.
Background technology
Diabetes (Diabetes Mellitus) are that what to be caused by Different types of etiopathogenises is the metabolism disorder disease of feature with the chronic hyperglycemia, are fatality rate after cardiovascular and cerebrovascular disease, cancer, the third-largest disease that disability rate is the highest.In recent years, along with reasons such as the raising of people's living standard, overnutrition, hypokinesia, the onset diabetes rate increases severely year by year, has become a kind of disease that has a strong impact on human health, also brings the tremendous economic burden to society.It is low that type 2 diabetes mellitus comes from the B cell function, insulin lacks and insulin resistant (Insulin Resistance relatively, IR), it shows as, and concentration of glucose raises unusually in the blood circulation, and causes the chronic pathological changes of many organ-tissues such as eye, kidney, nerve, blood vessel and heart.At present, the medicine of treatment type 2 diabetes mellitus mainly contains oral antidiabetic drug and insulin.In general, Western medicine determined curative effect, mechanism are clear and definite, still, but have various side effect.Though and Chinese medicine has the advantage for the treatment of both the principal and secondary aspects of a disease, safety, few side effects, effective in cure imprecise, deficiency such as mechanism is indeterminate.
Summary of the invention
One of technical problem to be solved by this invention provides a kind of pharmaceutical composition for the treatment of type 2 diabetes mellitus, and to overcome the insufficient shortcoming of existing western medical treatment, pharmaceutical composition of the present invention has the advantage of determined curative effect, few side effects.
Two of technical problem to be solved by this invention provides the preparation of drug combination method of above-mentioned treatment type 2 diabetes mellitus.
A kind of pharmaceutical composition for the treatment of type 2 diabetes mellitus as first aspect present invention comprises following component by weight ratio: 10～60 parts of the Radixs Astragali, 10～100 parts of Ganodermas, 5～30 parts of Fructus Ligustri Lucidi, 6～30 parts of Fructus Mumes.
Described pharmaceutical composition preferably includes following component by weight ratio: 10 parts of the Radixs Astragali, 10 parts of Ganodermas, 10 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Mumes.
Described pharmaceutical composition preferably includes following component by weight ratio: 30 parts of the Radixs Astragali, 10 parts of Ganodermas, 15 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Mumes.
Described pharmaceutical composition preferably includes following component by weight ratio: 30 parts of the Radixs Astragali, 30 parts of Ganodermas, 15 parts of Fructus Ligustri Lucidi, 15 parts of Fructus Mumes.
Described pharmaceutical composition preferably includes following component by weight ratio: 60 parts of the Radixs Astragali, 30 parts of Ganodermas, 30 parts of Fructus Ligustri Lucidi, 30 parts of Fructus Mumes.
Described pharmaceutical composition preferably includes following component by weight ratio: 40 parts of the Radixs Astragali, 30 parts of Ganodermas, 20 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Mumes.
Described pharmaceutical composition can be made into acceptable forms on any pharmaceutics in pill, granule, tablet, syrup, mixture, oral liquid, drop pill, capsule, the injection.
Preparation of drug combination method as the treatment type 2 diabetes mellitus of second aspect present invention, take by weighing the Radix Astragali at first in proportion respectively, Ganoderma, Fructus Ligustri Lucidi and Fructus Mume, and respectively add 6 times of decoctings respectively and boil 2 times, the 1st time 2-5 hour, the 2nd time 0.5-3 hour, merge each component and each time decocting liquid, filter, filtrate is concentrated into relative density 1.0～1.2, adds ethanol, stir evenly, leave standstill, get supernatant and reclaim ethanol, continue to be condensed into relative density and be 1.3～1.5 extractum, further spray drying, get extract powder, add an amount of excipient substance except that sucrose, mixing, granulate, promptly get granular pattern treatment type 2 diabetes mellitus pharmaceutical composition.
Preparation of drug combination method as the treatment type 2 diabetes mellitus of second aspect present invention, take by weighing the Radix Astragali, Ganoderma, Fructus Ligustri Lucidi and Fructus Mume in proportion respectively, and respectively add 6 times of decoctings respectively and boil 2 times, the 1st time 2-5 hour, the 2nd time 0.5-3 hour, merge each component and each time decocting liquid, filter, filtrate is concentrated into extractum, spray drying, add starch, use 85% alcohol granulation, drying, 18 mesh sieve granulate, add carboxymethyl starch sodium and magnesium stearate, mixing, tabletting, coating, packing promptly gets tablet form treatment type 2 diabetes mellitus pharmaceutical composition.
Preparation of drug combination method as the treatment type 2 diabetes mellitus of second aspect present invention, take by weighing the Radix Astragali, Ganoderma, Fructus Ligustri Lucidi and Fructus Mume in proportion respectively, and respectively add 6 times of decoctings respectively and boil the 1st time 2-5 hour 2 times, the 2nd time 0.5-3 hour, merge each component and each time decocting liquid, filter, filtrate is concentrated into extractum, spray drying, get extract powder, encapsulated, promptly get capsule-type treatment type 2 diabetes mellitus pharmaceutical composition.
Preparation of drug combination method as the treatment type 2 diabetes mellitus of second aspect present invention, take by weighing the Radix Astragali, Ganoderma, Fructus Ligustri Lucidi and Fructus Mume in proportion respectively, clean roguing, be ground into fine powder after the oven dry, cross mix homogeneously behind 100～200 mesh sieves, the fill capsule promptly gets capsule-type treatment type 2 diabetes mellitus pharmaceutical composition.
Preparation of drug combination method of the present invention is not limited to above-mentioned disclosed severally, can also be other known methods that industry technical staff is known.
The present invention is divided into treatment group and matched group at random with 60 routine cases, wherein, 30 examples are organized in treatment, matched group 30 examples, the treatment group is in former Western medicine glucose-lowering treatment, add treatment type 2 diabetes mellitus pharmaceutical composition of the present invention, matched group then continues former Western medicine glucose-lowering treatment and adds placebo simultaneously, the March course of treatment.
One, the clinical symptoms change of diabetics before and after the treatment:
The result shows: pharmaceutical composition of the present invention can obviously improve patient's symptom, and its improvement rate is apparently higher than matched group (P＜0.05), and concrete numerical value sees Table 1.
Clinical symptoms improvement rate relatively before and after the table 1 liang group treatment
Annotate: relatively preceding with treatment,
*P＜0.05; Compare between two groups of treatment back groups,
△P＜0.05.
Two, empty stomach, 2 hours after the meal blood glucose, glycolated hemoglobins change before and after the treatment:
The result shows: treatment group fasting glucose, after the meal 2h blood glucose all than taking a turn for the better (P＜0.01) before the treatment, matched group only fasting glucose improves (P＜0.05), treatment group simultaneously reduce fasting glucose and after the meal 2h blood glucose all be better than matched group (P＜0.05; P＜0.01); The treatment group reduces glycolated hemoglobin and is better than matched group (P＜0.05), and concrete numerical value is respectively referring to table 2 and table 3.
Before and after the treatment of table 2 liang group on an empty stomach and 2 hours after the meal blood glucose value (mmol/L) relatively
Notes: two groups of treatment backs are relatively preceding with treatment
*P＜0.05;
*P＜0.01; The treatment back is relatively between two groups:
△P＜0.05.
Comparison before and after the treatment of table 3 glycolated hemoglobin
Annotate: compare behind two groups of internal therapies with before the treatment
*P＜0.01; Compare between two groups of treatment back groups:
△P＜0.05
Three, two groups of super sensitive C-reactive proteins in treatment front and back change:
The result shows: decline (P＜0.05) is in various degree all arranged before and after treatment group and the treatment of control group; Treatment group decline degree is better than matched group (P＜0.05), and concrete numerical value is referring to table 4.
Table 4 surpasses the comparison before and after the sensitive C-reactive protein treatment
Annotate: compare behind two groups of internal therapies with before the treatment
*P＜0.05; Compare between two groups of treatment back groups:
△P＜0.05.
Four, two groups of treatment front and back fasting insulin (FINS), insulin resistance index (HOMA-IR) compares:
The result shows: treatment back treatment group and matched group FINS and HOMA-IR all have reduction (P＜0.05);
The treatment group all is better than matched group (P＜0.05) reducing insulin level and improve insulin resistance index, and concrete numerical value is referring to table 5.
Table 5 fasting insulin, the comparison before and after C peptide and the insulin resistance index treatment
Annotate: compare before and after two groups of treatments
*P＜0.05,
*P＜0.01; Compare between two groups after the treatment:
△P＜0.05,
△ △P＜0.01.
Each medicine material of the present invention, its pharmacological action is as follows respectively:
The Radix Astragali: sweet in the mouth, warm in nature, return spleen, lung meridian, have tonifying Qi and lifting yang, quench the thirst, benefit is defended consolidating superficial resistance, the effect of expelling pus and promoting granulation, inducing diuresis to remove edema, logical blood circulation regulating, popular meridians.Radix Astragali main component contains number of chemical compositions such as Saponin, polysaccharide, flavone, several amino acids and trace element, in addition, has in the report Radix Astragali and also contains compositions such as folic acid, linolenic acid, choline.Modern pharmacological research finds that the Radix Astragali can increase liver glycogen, and carbohydrate metabolism is had regulating action; Astragalus polysaccharides can strengthen the serine phosphorylation PKB expression of insulin stimulating, thereby improves insulin resistant.The Radix Astragali is Wheat Protein also, and energy enhancement of SOD and GSH-Px activity alleviate the Radical Metabolism disorder.
Ganoderma: the little acid of sweet in the mouth, property is flat, and GUIXIN, lung, liver, kidney channel have the beneficial motive, pacify smart soul, tonifying liver QI invigorating, hard muscles and bones, strengthening by means of tonics, life lengthening, sharp joint, control deaf curative effect.The complex chemical composition of Ganoderma, kind, totally 10 big classes surplus separation has obtained 100 from Ganoderma at present: polysaccharide, triterpenes, ucleosides, furans, sterols, alkaloids, aminoacid protein class, oils, inorganic ions, organic germanium etc.Pharmacological research shows, Ganoderma all has tangible regulating action to diabetes rat sugar, disorders of lipid metabolism, and can obviously reduce microdose urine protein excretion rate and the morphological abnormalities of early diabetic nephropathy rat, the diabetes rat body weight is obviously increased, renal index reduces, total serum protein, albumin increase, and Ganoderma has certain effect to the diabetic mice early nephropathy.Thereby ganoderan can help glucose transport to go into the B cell by promoting the proteic expression of islet cells GLUT2, promotes the metabolism of glucose, causes the outer Ca of islet cells
2+In stream and play the effect that pancreotropic hormone discharges.
Fructus Ligustri Lucidi: sweet in the mouth, hardship, cool in nature.Return liver, kidney channel.Main effect, nourishing the liver and kidney, black hair makes eye bright.Mainly contain terpenoid, flavonoid, the plain class of phenylpropyl alcohol and some alcohol, phenolic compound in the Fructus Ligustri Lucidi platymiscium.Oleanolic acid wherein, five rings such as maloic acid three mushrooms compositions are the main effective ingredient of Ligustrum plant.Fructus Ligustri Lucidi has prevention and therapeutical effect to hyperglycemia, and two kinds of effective ingredient of contained ursolic acid and oleanolic acid all have blood sugar reducing function, can obviously increase diabetes model Hepar Mus glycogen content and blood sugar lowering; Fructus Ligustri Lucidi also has the enhance immunity active function, gives mouse stomach with the Fructus Ligustri Lucidi decoct, can make the mouse immune organ, and thymus and spleen weight obviously increase, and oleanolic acid can increase macrophage and lymphocytic function; In preventing and treating the experiment of hyperlipemia and atherosclerosis, can blood fat reducing concentration.
Fructus Mume: sour in the mouth, puckery is flat.Return liver, spleen, lung, large intestine channel.Main effect: promoting the production of body fluid to quench thirst, astringing lung-QI and relieving cough, relieving diarrhea with astringents, relieving pain by calming ascaris.Fructus Mume is that the ripe or method of maturescent fruit through smoking or smoking of rose department plant plum processes.Fructus Mume contains rich organic acid, sterols, aminoacid volatile oil, lipoid, has effects such as antibacterial, anthelmintic, antitumor, antiallergic.
The pharmaceutical composition of type 2 diabetes mellitus of the present invention can effectively reduce empty stomach, post-prandial glycemia, glycolated hemoglobin, and the state that effectively reduces inflammation has a better role to type 2 diabetes mellitus patient's insulin resistant tool.
The specific embodiment
For technological means, creation characteristic that the present invention is realized, reach purpose and effect is easy to understand, below in conjunction with instantiation, further set forth the present invention.
Embodiment 1
Raw material takes by weighing by following weight proportion:
10 parts of the Radixs Astragali, 10 parts of Ganodermas, 10 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Mumes.
Get above medicine, add 6 times of decoctings and boil 2 times, the 1st time 3 hours, the 2nd time 2 hours, merge each each time of component decocting liquid, filter, filtrate is concentrated into relative density 1.2, adds ethanol, stirs evenly, leave standstill, get supernatant and reclaim ethanol, be condensed into extractum, spray drying gets extract powder, adds an amount of excipient substance except that sucrose, mixing is granulated, and promptly gets granular pattern treatment type 2 diabetes mellitus pharmaceutical composition of the present invention.Three times on the one, each 4.
Embodiment 2
Raw material takes by weighing by following weight proportion:
30 parts of the Radixs Astragali, 10 parts of Ganodermas, 15 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Mumes.
Get above medicine, add 6 times of decoctings and boil 2 times, the 1st time 3 hours, the 2nd time 2 hours, collecting decoction filtered, and filtrate is concentrated into extractum, and spray drying gets extract powder, and is encapsulated, promptly got capsule-type treatment type 2 diabetes mellitus pharmaceutical composition of the present invention.Three times on the one, each 4 capsules.
Embodiment 3
Raw material takes by weighing by following weight proportion:
30 parts of the Radixs Astragali, 30 parts of Ganodermas, 15 parts of Fructus Ligustri Lucidi, 15 parts of Fructus Mumes.
Get above medicine, raw material is cleaned roguing, be ground into fine powder after the oven dry, mix homogeneously behind mistake 100～200 mesh sieves, last fill capsule promptly gets capsule-type treatment type 2 diabetes mellitus pharmaceutical composition of the present invention.Three times on the one, each 4 capsules.
Embodiment 4
Raw material takes by weighing by following weight proportion:
60 parts of the Radixs Astragali, 30 parts of Ganodermas, 30 parts of Fructus Ligustri Lucidi, 30 parts of Fructus Mumes.
Get above medicine, add 6 times of decoctings and boil 2 times, the 1st time 3 hours, the 2nd time 2 hours, collecting decoction filtered, filtrate is concentrated into extractum, and spray drying adds starch, use 85% alcohol granulation, drying, 18 mesh sieve granulate, add carboxymethyl starch sodium and magnesium stearate, mixing, tabletting, coating, packing promptly gets tablet form treatment type 2 diabetes mellitus pharmaceutical composition of the present invention.Three times on the one, each 4.
Embodiment 5
Raw material takes by weighing by following weight proportion:
Radix Astragali 40g, Ganoderma 30g, Fructus Ligustri Lucidi 20g, Fructus Mume 10g.
With the Impurity removal of above-mentioned each raw material, all medicines of receiving add 500 milliliters in water in marmite earlier, soak 30 minutes, decoct half an hour, and potion on the one is taken at twice.
More than show and described ultimate principle of the present invention and principal character and advantage of the present invention.The technical staff of the industry should understand; the present invention is not restricted to the described embodiments; that describes in the foregoing description and the description just illustrates principle of the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.The claimed scope of the present invention is defined by appending claims and equivalent thereof.
Claims (11)
1. a pharmaceutical composition for the treatment of type 2 diabetes mellitus is characterized in that, comprises following component by weight ratio: 10～60 parts of the Radixs Astragali, 10～100 parts of Ganodermas, 5～30 parts of Fructus Ligustri Lucidi, 6～30 parts of Fructus Mumes.
2. pharmaceutical composition according to claim 1 is characterized in that, comprises following component by weight ratio: 10 parts of the Radixs Astragali, 10 parts of Ganodermas, 10 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Mumes.
3. pharmaceutical composition according to claim 1 is characterized in that, comprises following component by weight ratio: the Radix Astragali 30, Ganoderma 10, Fructus Ligustri Lucidi 15, Fructus Mume 10.
4. pharmaceutical composition according to claim 1 is characterized in that, comprises following component by weight ratio: 30 parts of the Radixs Astragali, 30 parts of Ganodermas, 15 parts of Fructus Ligustri Lucidi, 15 parts of Fructus Mumes.
5. pharmaceutical composition according to claim 1 is characterized in that, comprises following component by weight ratio: 60 parts of the Radixs Astragali, 30 parts of Ganodermas, 30 parts of Fructus Ligustri Lucidi, 30 parts of Fructus Mumes.
6. pharmaceutical composition according to claim 1 is characterized in that, comprises following component by weight ratio: 40 parts of the Radixs Astragali, 30 parts of Ganodermas, 20 parts of Fructus Ligustri Lucidi, 10 parts of Fructus Mumes.
7. according to each described pharmaceutical composition of claim 1 to 6, it is characterized in that described pharmaceutical composition is an acceptable forms on any pharmaceutics in pill, granule, tablet, syrup, mixture, oral liquid, drop pill, capsule, the injection.
8. according to the method for the pharmaceutical composition of the described preparation of claim 1 treatment type 2 diabetes mellitus, it is characterized in that, take by weighing the Radix Astragali in proportion respectively, Ganoderma, Fructus Ligustri Lucidi and Fructus Mume, and respectively add 6 times of decoctings respectively and boil 2 times, the 1st time 2-5 hour, the 2nd time 0.5-3 hour, merge each component and each time decocting liquid, filter, filtrate is concentrated into relative density 1.0～1.2, add ethanol, stir evenly, leave standstill, get supernatant and reclaim ethanol, continue to be condensed into relative density and be 1.3～1.5 extractum, further spray drying, extract powder, add an amount of excipient substance except that sucrose, mixing is granulated, and promptly gets granular pattern treatment type 2 diabetes mellitus pharmaceutical composition.
9. according to the method for the pharmaceutical composition of the described preparation of claim 1 treatment type 2 diabetes mellitus, it is characterized in that, take by weighing the Radix Astragali, Ganoderma, Fructus Ligustri Lucidi and Fructus Mume in proportion respectively, and respectively add 6 times of decoctings respectively and boil 2 times, the 1st time 2-5 hour, the 2nd time 0.5-3 hour, merge each each time of component decocting liquid, filter, filtrate is concentrated into extractum, spray drying adds starch, uses 85% alcohol granulation, dry, 18 mesh sieve granulate add carboxymethyl starch sodium and magnesium stearate, mixing, tabletting, coating, packing promptly gets tablet form treatment type 2 diabetes mellitus pharmaceutical composition.
10. according to the method for the pharmaceutical composition of the described preparation of claim 1 treatment type 2 diabetes mellitus, it is characterized in that, take by weighing the Radix Astragali, Ganoderma, Fructus Ligustri Lucidi and Fructus Mume in proportion respectively, and respectively add 6 times of decoctings respectively and boil 2 times, the 1st time 2-5 hour, the 2nd time 0.5-3 hour, merge each each time of component decocting liquid, filter, filtrate is concentrated into extractum, and spray drying gets extract powder, encapsulated, promptly get capsule-type treatment type 2 diabetes mellitus pharmaceutical composition.
11. the method for the pharmaceutical composition of type 2 diabetes mellitus is treated in described preparation according to claim 1, it is characterized in that, take by weighing the Radix Astragali, Ganoderma, Fructus Ligustri Lucidi and Fructus Mume in proportion respectively, clean roguing, be ground into fine powder after the oven dry, cross mix homogeneously behind 100～200 mesh sieves, the fill capsule promptly gets capsule-type treatment type 2 diabetes mellitus pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910048888 CN101856405B (en) | 2009-04-07 | 2009-04-07 | Medicinal composition for treating type II diabetes mellitus and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910048888 CN101856405B (en) | 2009-04-07 | 2009-04-07 | Medicinal composition for treating type II diabetes mellitus and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101856405A true CN101856405A (en) | 2010-10-13 |
| CN101856405B CN101856405B (en) | 2012-09-19 |
Family
ID=42942709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910048888 Active CN101856405B (en) | 2009-04-07 | 2009-04-07 | Medicinal composition for treating type II diabetes mellitus and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101856405B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600384A (en) * | 2012-03-05 | 2012-07-25 | 广州蓝韵医药研究有限公司 | Bamboo shoot product for treating diabetes mellitus and preparation method thereof |
| CN105213861A (en) * | 2015-11-07 | 2016-01-06 | 李树霞 | A kind of Chinese medicine and preparation method for the treatment of type 2 diabetes mellitus |
| CN106138757A (en) * | 2016-08-25 | 2016-11-23 | 陈红专 | A kind of pharmaceutical composition treating type Ⅱdiabetes mellitus and preparation method thereof |
| CN107669860A (en) * | 2017-09-26 | 2018-02-09 | 河南大学 | A kind of Chinese medicine composition and its application with blood sugar reducing function |
| CN110652590A (en) * | 2018-06-29 | 2020-01-07 | 上海复浩生物科技有限公司 | Traditional Chinese medicine compound for treating diabetes and preparation method and application thereof |
| CN111956747A (en) * | 2020-09-02 | 2020-11-20 | 陈爱红 | A pharmaceutical composition for treating type 2 diabetes and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100348220C (en) * | 2005-07-26 | 2007-11-14 | 浙江省中药研究所 | Chinese materia medica preparation for treating diabetic nephropathy, and preparation method |
| CN100566731C (en) * | 2006-12-07 | 2009-12-09 | 李永胜 | A kind of Qizhen capsule of enhancing immunity, oral liquid |
-
2009
- 2009-04-07 CN CN 200910048888 patent/CN101856405B/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600384A (en) * | 2012-03-05 | 2012-07-25 | 广州蓝韵医药研究有限公司 | Bamboo shoot product for treating diabetes mellitus and preparation method thereof |
| CN105213861A (en) * | 2015-11-07 | 2016-01-06 | 李树霞 | A kind of Chinese medicine and preparation method for the treatment of type 2 diabetes mellitus |
| CN106138757A (en) * | 2016-08-25 | 2016-11-23 | 陈红专 | A kind of pharmaceutical composition treating type Ⅱdiabetes mellitus and preparation method thereof |
| CN107669860A (en) * | 2017-09-26 | 2018-02-09 | 河南大学 | A kind of Chinese medicine composition and its application with blood sugar reducing function |
| CN110652590A (en) * | 2018-06-29 | 2020-01-07 | 上海复浩生物科技有限公司 | Traditional Chinese medicine compound for treating diabetes and preparation method and application thereof |
| CN111956747A (en) * | 2020-09-02 | 2020-11-20 | 陈爱红 | A pharmaceutical composition for treating type 2 diabetes and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101856405B (en) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN100368006C (en) | Medicine for treating cardiovascular disease | |
| CN1895547B (en) | Medicine for treating diabetes and its preparation | |
| CN101744970B (en) | Medicine used for type 2 diabetes and preparation method thereof | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN104815166B (en) | A kind of Chinese medicine composition for treating diabetes and its preparation and application | |
| CN101513492A (en) | Chinese medicament for treating diabetes | |
| CN101279034B (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN101167846A (en) | Capsule with blood sugar reducing function and preparation method thereof | |
| CN1066332C (en) | Hypoglycemic compound capsule | |
| CN102114189A (en) | Chinese medicinal blood glucose reducing tablet for treating diabetes comprising superfine powder | |
| CN101745048B (en) | Medicine for treating type II diabetes and resisting aging | |
| CN104258359A (en) | Traditional Chinese medicine combination for curing pregnancy reaction and preparation method of preparations thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN1192789C (en) | 'Shenhuaxiaokecha' tea and preparing method thereof | |
| CN105055851A (en) | Chinese medicinal composition for treatment of diabetes, preparation and application thereof | |
| CN100398123C (en) | Medicine for treating diabetes of blood stasis complicated kidney spleen deficiency type | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN1287836C (en) | Chinese medicinal powder for treating diabetes and its production method | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN101152395B (en) | Chinese medicine for treating diabetes | |
| CN1076622C (en) | Chinese medicine for curing nephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |